Skip to main content

Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis.

Publication ,  Journal Article
Morris, TA; Marsh, JJ; Chiles, PG; Auger, WR; Fedullo, PF; Woods, VL
Published in: Am J Respir Crit Care Med
June 1, 2006

RATIONALE: Although acute pulmonary embolism is epidemiologically associated with chronic thromboembolic pulmonary hypertension, the factors responsible for resistance to thrombolysis and a shift toward vascular remodeling within the pulmonary arteries of patients with chronic thromboembolic pulmonary hypertension are unknown. OBJECTIVE: Determine whether fibrin from patients is more resistant to plasmin-mediated lysis than fibrin from healthy control subjects. METHODS: Fibrinogen purified from patients and control subjects was used to prepare fibrin clots, which were subsequently digested with plasmin for various periods of time. The degradation of the alpha-, beta-, and gamma-chains of fibrin and the appearance of peptide fragments over time were assessed by polyacrylamide gel electrophoresis and Western blotting. MEASUREMENTS AND MAIN RESULTS: Densitometry of Coomassie-stained gels revealed significantly slower cleavage of all three polypeptide chains of fibrin from patients compared with control subjects (p < 0.05). In particular, release of N-terminal fragments from the beta-chain of fibrin, which promote cell signaling, cell migration, and angiogenesis, was retarded in patients compared with control subjects (p < 0.01). CONCLUSIONS: The relative resistance of patient fibrin to plasmin-mediated lysis may be due to alterations in fibrin(ogen) structure affecting accessibility to plasmin cleavage sites. The persistence of structural motifs of fibrin, such as the beta-chain N-terminus, within the pulmonary vasculature could promote the transition from acute thromboemboli into chronic obstructive vascular scars.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Respir Crit Care Med

DOI

ISSN

1073-449X

Publication Date

June 1, 2006

Volume

173

Issue

11

Start / End Page

1270 / 1275

Location

United States

Related Subject Headings

  • alpha-2-Antiplasmin
  • Thrombolytic Therapy
  • Respiratory System
  • Pulmonary Embolism
  • Plasminogen
  • Middle Aged
  • Male
  • Hypertension, Pulmonary
  • Humans
  • Fibrinolytic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morris, T. A., Marsh, J. J., Chiles, P. G., Auger, W. R., Fedullo, P. F., & Woods, V. L. (2006). Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med, 173(11), 1270–1275. https://doi.org/10.1164/rccm.200506-916OC
Morris, Timothy A., James J. Marsh, Peter G. Chiles, William R. Auger, Peter F. Fedullo, and Virgil L. Woods. “Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis.Am J Respir Crit Care Med 173, no. 11 (June 1, 2006): 1270–75. https://doi.org/10.1164/rccm.200506-916OC.
Morris TA, Marsh JJ, Chiles PG, Auger WR, Fedullo PF, Woods VL. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med. 2006 Jun 1;173(11):1270–5.
Morris, Timothy A., et al. “Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis.Am J Respir Crit Care Med, vol. 173, no. 11, June 2006, pp. 1270–75. Pubmed, doi:10.1164/rccm.200506-916OC.
Morris TA, Marsh JJ, Chiles PG, Auger WR, Fedullo PF, Woods VL. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med. 2006 Jun 1;173(11):1270–1275.

Published In

Am J Respir Crit Care Med

DOI

ISSN

1073-449X

Publication Date

June 1, 2006

Volume

173

Issue

11

Start / End Page

1270 / 1275

Location

United States

Related Subject Headings

  • alpha-2-Antiplasmin
  • Thrombolytic Therapy
  • Respiratory System
  • Pulmonary Embolism
  • Plasminogen
  • Middle Aged
  • Male
  • Hypertension, Pulmonary
  • Humans
  • Fibrinolytic Agents